September 1, 2026
Lung Cancer Progress Is Driving Down Cancer Deaths
The CDC’s 2026 report finds falling lung cancer death rates are the biggest reason U.S. cancer mortality keeps declining after more than 20 years.
CDC Newsroom
Research News
Explore our curated selection of the latest breakthroughs in lung cancer research.
September 1, 2026
The CDC’s 2026 report finds falling lung cancer death rates are the biggest reason U.S. cancer mortality keeps declining after more than 20 years.
CDC Newsroom
July 31, 2026
A large new study finds that Veterans with lung cancer who get care through the Veterans Health Administration (VA) are surviving longer than people treated at other U.S. hospitals.
Researchers looked at more than 1.4 million people diagnosed with non-small cell lung cancer, the most common type, between 2007 and 2019. They compared about 79,000 Veterans treated at the VA with about 1.38 million patients treated at community hospitals across the country.
In 2007, both groups had the same chance of being alive three years after diagnosis: 24%. By 2019, that number had climbed to 51% for Veterans treated at the VA, compared with 41% for patients treated elsewhere. The VA also did better than academic and research hospitals, which reached 46%.
The difference showed up at every stage of the disease. That stands out because the Veterans in the study were older and had more health problems than the other patients.
What might explain it? In an editorial about the study, Dr. Drew Moghanaki, a member of LCFA’s Scientific Advisory Board, and his co-authors point to how VA care is organized. National programs guide surgery, radiation and cancer medicine. Most VA medical centers partner with academic medical centers. Teams of specialists review cases together. And Veterans can get help with housing, money and transportation, the kinds of problems that can interrupt treatment.
The study did not prove why the VA did better, and it doesn’t mean every VA hospital does better than every other hospital. But it shows what’s possible when care is built around the whole person.
What this means for you: if you are a Veteran, ask your VA care team whether lung cancer screening is right for you. Finding lung cancer early gives you more treatment options.
Journal of the National Cancer Institute
July 22, 2026
Patients with ROS1 lung cancer have a new option. On July 22, 2026, the FDA approved zidesamtinib, sold as Jideytro. The maker is Nuvalent, Inc.
U.S. Food & Drug Administration
July 20, 2026
Discover why 9 in 10 lung cancer patients miss out on clinical trial discussions and how asking one key question early can unlock life-saving options.
patch.com
May 31, 2026
A new lung cancer drug is making headlines. At the 2026 ASCO meeting, researchers shared exciting results for a drug called ivonescimab. In a large study, it lowered the risk of death by 34% for people with a hard-to-treat type of lung cancer.
Fierce Pharma
May 29, 2026
Pfizer
June 5, 2025
Dr. Ramalingam emphasizes community oncologists must prioritize molecular testing and lung cancer screening to improve patient access to treatments.
Targeted Oncology
May 11, 2025
Study reveals lung cancer itself causes brain structural changes and cognitive impairment in patients before receiving any chemotherapy treatment.
Nature
February 21, 2025
Comprehensive review examining molecular mechanisms of cancer invasion and metastasis, identifying potential therapeutic targets for preventing cancer spread.
Nature
February 21, 2025
Final clinical trial results demonstrate selpercatinib’s safety and efficacy in treating RET fusion-positive non-small cell lung cancer patients.
Journal of Clinical Oncology
October 31, 2024
The White House Briefing Room
September 12, 2023
At 22, Leah Hubbard faces advanced lung cancer potentially linked to teenage pregnancy, challenging assumptions about the disease and raising awareness.
The U.S. Sun
Learn more about:
LCFA prioritizes providing reliable information about new diagnostics, treatments, and prevention strategies, including exciting FDA-approved personalized therapies based on individual tumor biomarkers. Human-reviewed, AI-created content is used to create some of the summaries for the articles listed.